New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2013
13:43 EDTGSK, SRPTDuchenne muscular dystrophy patients hospitalized, TheStreet says
Duchenne muscular dystrophy patients treated with drisapersen, GlaxoSmithKline's (GSK) experimental drug, have been hospitalized, according to a report by TheStreet that cites a Glaxo scientist speaking in Rome last Sunday. The report notes that Sarepta Therapeutics (SRPT) is meeting with the FDA this quarter to discuss the possibility of an accelerated approval filing for its Duchenne muscular dystrophy drug eteplirsen. Reference Link
News For GSK;SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 20, 2015
09:05 EDTSRPTSarepta price target raised to $45 from $22 at Roth Capital
Subscribe for More Information
08:40 EDTSRPTJMP Securities still cautious on Sarepta eteplirsen outlook
Subscribe for More Information
08:34 EDTSRPTSarepta upgraded on eteplirsen NDA submission at SunTrust
Subscribe for More Information
08:10 EDTSRPTSarepta price target raised to $20 from $15 at RBC Capital
Subscribe for More Information
07:46 EDTGSKDeutsche Bank positive on potential Pfizer, GSK merger
Deutsche Bank analyst Gregg Gilbert believes a large foreign deal for Pfizer (PFE) may make sense and says a buyout of GlaxoSmithKline (GSK) could be "materially" accretive to earnings while improving the company's tax situation over time. Gilbert assumes a $60 per share buyout price for GlaxoSmithKline in a research note this morning titled "Introducing 'PfizerKline'". The stock closed yesterday up 2c to $44.68. Gilbert reiterates a Buy rating on Pfizer with a $41 price target. Shares ended yesterday up 23c to $34.21.
07:36 EDTSRPTSarepta upgraded to Buy at Canaccord
Subscribe for More Information
06:40 EDTSRPTSarepta upgraded to Buy from Hold at Canaccord
Subscribe for More Information
06:34 EDTSRPTSarepta upgraded to Buy from Neutral at SunTrust
Price target is $33.
May 19, 2015
19:06 EDTSRPTOn The Fly: After Hours Movers
UP AFTER EARNINGS: Computer Sciences (CSC), up 5%... NQ Mobile (NQ), up 1.4%. ALSO HIGHER: Sarepta Therapeutics (SRPT), up 38.9% after announcing plans for rolling eteplirsen NDA... LendingClub (LC), up 2.8% after being upgraded to Overweight from Equal Weight at Morgan Stanley. DOWN AFTER EARNINGS: Keysight Technologies (KEYS), down 3.1%... Autodesk (ADSK), down 2.1%. ALSO LOWER: Cimarex Energy (XEC), down 4% after filing to sell 6M shares of common stock... Norwegian Cruise Line (NCLH), down 2.5% after filing to sell 20M ordinary shares for holders... Achillion Pharmaceuticals (ACHN), down 3.2% following collaboration for HCV with Janssen.
16:11 EDTSRPTSarepta up 36% to $22.28 after announcing plans for rolling eteplirsen NDA
Subscribe for More Information
16:04 EDTSRPTSarepta to submit rolling eteplirsen NDA, sees complete submission by mid-year
Subscribe for More Information
16:02 EDTSRPTSarepta plans to complete Eteplirsen NDA submission by mid-year
16:01 EDTSRPTSarepta says to submit first two components of Eteplirsen NDA this week
Subscribe for More Information
16:01 EDTSRPTSarepta to submit rolling NDA for Eteplirsen following meeting with FDA
Subscribe for More Information
09:25 EDTGSKGlaxoSmithKline asthma drug overused, risks underappreciated, ProPublica says
Subscribe for More Information
06:55 EDTGSKGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 15, 2015
15:11 EDTGSKGlaxoSmithKline reports 16.12% stake in HTG Molecular
Subscribe for More Information
09:31 EDTGSKAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
May 13, 2015
11:38 EDTGSKGlaxoSmithKline downgraded to Neutral from Buy at UBS
Subscribe for More Information
07:07 EDTGSKGSK, Emergent BioSolutions, Oxford initiate Prime Boost study of Ebola vaccine
A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara, or MVA, Ebola Zaire vaccine candidate, or MVA EBOZ, as a prime-boost to GlaxoSmithKline's (GSK) Chimp Adenovirus type 3, or ChAd3, Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom's Medicines and Healthcare Products Regulatory Agency, or MHRA. The phase 1 study has a planned enrollment of 38 volunteers of which 6 will receive MVA EBOZ only while the other 32 will receive ChAd3-EBO-Z prime followed by MVA EBOZ boost. Emergent BioSolutions (EBS) manufactured the supply of MVA EBOZ to be used in this phase 1 study, which is being conducted in the U.K. with support from the Wellcome Trust and the U.K. Department for International Development.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use